文献速递肿瘤 PET/CT

FDG PET-CT可改变适合根治性治疗的胃腺癌患者管理

Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-08-03

回顾性分析英国三级中心330例胃腺癌患者,其中105例治疗前接受FDG PET-CT分期。86%原发肿瘤代谢活跃,肠型摄取率高于非肠型(93% vs 78%,p=0.005)。FDG PET-CT使20例(19%)淋巴结或转移分期上调,17例检出其他影像未见的远处转移;组织学分析30例中,淋巴结受累灵敏度40%、特异度73%。

要点

  • FDG PET-CT使19%胃腺癌患者分期上调,主要因检出其他影像未见的远处转移。
  • 肠型胃腺癌原发灶代谢活跃比例高于非肠型(93% vs 78%,p=0.005)。
  • FDG PET-CT对淋巴结受累灵敏度低(40%)但特异度较高(73%)。

核心结论

  • FDG PET-CT在临床有用比例的患者中提供新信息并改变治疗策略,最常见为检出其他影像未见的远处转移,尤其肠型肿瘤。

研究设计与样本

  • FDG PET-CT定性和定量(SUVmax)评估,与分期诊断CT及30例手术切除者病理结果比较。

主要发现

  • 105例中86%原发肿瘤代谢活跃(摄取高于正常胃),肠型41/44(93%)SUVmax 14.1±1.3,非肠型36/46(78%)SUVmax 9.0±0.9,p=0.005。
  • FDG PET-CT使20例(19%;肠型13例、非肠型6例、未报告1例)淋巴结或转移分期上调,17例检出其他影像未见的远处转移。
  • 30例组织学分析中,FDG PET-CT对淋巴结受累灵敏度40%、特异度73%。

临床怎么用

  • 对适合根治性治疗的胃腺癌患者,尤其肠型,可考虑FDG PET-CT分期以检出其他影像未见的远处转移并调整治疗策略。
  • FDG PET-CT对淋巴结受累灵敏度低,阴性结果不能排除淋巴结转移。

局限性

  • 回顾性单中心研究,仅105例接受FDG PET-CT,手术病理对照仅30例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: 18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) is valuable in the management of patients with oesophageal cancer, but a role in gastric cancer staging is debated. Our aim was to review the role of FDG PET-CT in a large gastric cancer cohort in a tertiary UK centre. METHODS: We retrospectively reviewed data from 330 patients presenting with gastric adenocarcinoma between March 2014 and December 2016 of whom 105 underwent pre-treatment staging FDG PET-CT scans. FDG PET-CT scans were graded qualitatively and quantitatively (SUVmax) and compared with staging diagnostic CT and operative pathology results (n = 30) in those undergoing resection. RESULTS: Of the 105 patients (74 M, median age 73 years) 86% of primary tumours were metabolically active (uptake greater than normal stomach) on FDG PET-CT [41/44 (93%) of the intestinal histological subtype (SUVmax 14.1 ± 1.3) compared to 36/46 (78%) of non-intestinal types (SUVmax 9.0 ± 0.9), p = 0.005]. FDG PET-CT upstaged nodal or metastastic staging of 20 patients (19%; 13 intestinal, 6 non-intestinal, 1 not reported), with 17 showing distant metastases not evident on other imaging. On histological analysis, available in 30 patients, FDG PET-CT showed low sensitivity (40%) but higher specificity (73%) for nodal involvement. CONCLUSION: FDG PET-CT provides new information in a clinically useful proportion of patients, which leads to changes in treatment strategy, most frequently by detecting previously unidentified metastases, particularly in those with intestinal-type tumours.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bosch KD, Chicklore S, Cook GJ, et al. Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. Eur J Nucl Med Mol Imaging. 2019. PMID: 31377821. doi:10.1007/s00259-019-04429-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。